Preliminary phase I results from a first-in-human study of ZG006, a trispecific anti-T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer or neuroendocrine carcinoma

被引：0

作者：

Wang, Q. ^{[1
]}

Chai, X. ^{[2
]}

Lin, R. ^{[3
]}

Zheng, L. ^{[4
]}

Cao, D. ^{[5
]}

Qu, X. ^{[6
]}

Liu, L. ^{[7
]}

Wu, L. ^{[8
]}

Mou, H. ^{[9
]}

Xu, Q. ^{[10
]}

Shi, J. ^{[11
]}

机构：

[1] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R China

[2] ChangSha TaiHe Hosp, Dept Oncol, Changsha, Peoples R China

[3] Fujian Canc Hosp, Dept Abdominal Oncol, Fujian, Peoples R China

[4] Sichuan Univ, West China Hosp, Clin Trial Ctr, Chengdu, Peoples R China

[5] Sichuan Univ, West China Hosp, Dept Abdominal Oncol, Chengdu, Peoples R China

[6] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Peoples R China

[7] Jilin Univ, China Japan Union Hosp, Phase Clin Trial Ctr 1, Changchun, Peoples R China

[8] Shulan Hangzhou Hosp, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China

[9] Shulan Hangzhou Hosp, Dept Oncol, Hangzhou, Peoples R China

[10] Zhejiang Canc Hosp, Dept Hepatobiliary & Pancreat Gastroenterol, Hangzhou, Peoples R China

[11] Linyi Canc Hosp, Dept Med Oncol, Linyi, Shandong, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.752

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

686TiP

引用

页码：S532 / S533

页数：2

共 50 条

[21] AMG 757, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer
Cooke, K.
Estrada, J.
Zhan, J.
Werner, J.
Bailis, J.
Hughes, P.
Shetty, A.
Canon, J.
Smit, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S343 - S344
[22] Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)
Paz-Ares, L.
Owonikoko, T. K.
Johnson, M.
Govindan, R.
Izumi, H.
Lai, V.
Borghaei, H.
Boyer, M.
Boosman, R. J.
Hummel, H-D.
Blackhall, F.
Dowlati, A.
Zhang, Y.
Mukherjee, S.
Sable, B.
Pati, A.
Shetty, A.
Sadraei, N. Hashemi
Champiat, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S720 - S721
[23] DLL3 analysis of circulating tumor cells predict treatment outcome in phase 1 rova-T study in small cell lung cancer
Roy, Somdutta
Martinez, Kevin
Dilip, Archana
Karsunky, Holger
Dylla, Scott
CANCER RESEARCH, 2017, 77
[24] A PHASE 1B, OPEN-LABEL, DOSE-ESCALATION TRIAL OF THE DELTA-LIKE LIGAND 3 (DLL3)/CD3 IGG-LIKE T CELL ENGAGER, BI 764532, IN PATIENTS WITH DLL3-POSITIVE GLIOMA
van den Bent, Martin
Roth, Patrick
Tabatabai, Ghazaleh
Burger, Michael C.
Martinez-Garcia, Maria
von Baumgarten, Louisa
Greil, Richard
Studeny, Matus
Simetzberger, Monika
Liu, Meiruo
NEURO-ONCOLOGY, 2023, 25
[25] QLS31904: An anti-DLL3/CD3 bispecific antibody for T cell immunotherapy of small cell lung cancer.
Yang, Liuqing
Li, Ruimei
Jiang, Jiahua
Qian, Hongliang
Ge, Hongxiu
Lu, Ting
Fang, Yan
Liu, Jun
Zhao, Shuyong
CANCER RESEARCH, 2022, 82 (12)
[26] Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE®) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)
Ramalingam, S. S.
Ahn, M-J.
Akamatsu, H.
Blackhall, F.
Borghaei, H.
Hummel, H-D.
Johnson, M.
Reck, M.
Zhang, Y.
Jandial, D.
Cheng, S.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2022, 33 : S103 - S104
[27] Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression
Vitorino, Philip
Chuang, Chen-Hua
Iannello, Alexandre
Zhao, Xi
Anderson, Wade
Ferrando, Ronald
Zhang, Zhaomei
Madhavan, Shravanthi
Karsunky, Holger
Saunders, Laura R.
TRANSLATIONAL ONCOLOGY, 2021, 14 (01):
[28] Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Zhou, Di
Byers, Lauren A.
Sable, Beate
Smit, Marie-Anne Damiette
Sadraei, Nooshin Hashemi
Dutta, Sandeep
Upreti, Vijay V.
JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (03): : 362 - 370
[29] Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).
Owonikoko, Taofeek K.
Champiat, Stephane
Johnson, Melissa Lynne
Govindan, Ramaswamy
Izumi, Hiroki
Lai, W. Victoria Victoria
Borghaei, Hossein
Boyer, Michael J.
Boosman, Rene J.
Hummel, Horst-Dieter
Blackhall, Fiona Helen
Reguart, Noemi
Dowlati, Afshin
Zhang, Yiran
Mukherjee, Sujoy
Minocha, Mukul
Zhou, Yanchen
Shetty, Aditya
Sadraei, Nooshin Hashemi
Paz-Ares, Luis G.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[30] Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Mikami, Hirofumi
Feng, Shu
Matsuda, Yutaka
Ishii, Shinya
Naoi, Sotaro
Azuma, Yumiko
Nagano, Hiroaki
Asanuma, Kentaro
Kayukawa, Yoko
Tsunenari, Toshiaki
Kamikawaji, Shogo
Iwabuchi, Ryutaro
Shinozuka, Junko
Yamazaki, Masaki
Kuroi, Haruka
Ho, Samantha Shu Wen
Gan, Siok Wan
Chichili, Priyanka
Pang, Chai Ling
Yeo, Chiew Ying
Shimizu, Shun
Hironiwa, Naoka
Kinoshita, Yasuko
Shimizu, Yuichiro
Sakamoto, Akihisa
Muraoka, Masaru
Takahashi, Noriyuki
Kawa, Tatsuya
Shiraiwa, Hirotake
Mimoto, Futa
Kashima, Kenji
Kamata-Sakurai, Mika
Ishikawa, Shumpei
Aburatani, Hiroyuki
Kitazawa, Takehisa
Igawa, Tomoyuki
CANCER IMMUNOLOGY RESEARCH, 2024, 12 (06) : 719 - 730

← 1 2 3 4 5 →